

ASTRAZENECA PLC  
Form 6-K  
March 28, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of (March 2018)

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA  
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):  
82- \_\_\_\_\_

AstraZeneca PLC

INDEX TO EXHIBITS

Director/PDMR Shareholding

28 March 2018 15:00 BST

TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 27 March 2018, awards of the Company's ordinary shares of \$0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP).

The AZDBP award was granted on 27 March 2015, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2014 performance into Ordinary Shares, and vested on completion of the three-year holding period.

Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below:

PDMR	Ordinary Shares acquired under the AZDBP
Pascal Soriot	11,998
Marc Dunoyer	3,768

For tax purposes, the fair market value of an Ordinary Share at vest was 4760.0 pence, being the closing price on the last trading day preceding the vesting day.

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

Media Relations

Esra Erkal-Paler	UK/Global	+44 203 749 5638
Karen Birmingham	UK/Global	+44 203 749 5634
Rob Skelding	UK/Global	+44 203 749 5821
Matt Kent	UK/Global	+44 203 749 5906
Gonzalo Viña	UK/Global	+44 203 749 5916
Jacob Lund	Sweden	+46 8 553 260 20
Michele Meixell	US	+1 302 885 2677

Investor Relations

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Thomas Kudsk Larsen		+44 203 749 5712
Craig Marks	Finance; Fixed Income; M&A	+44 7881 615 764
Henry Wheeler	Oncology	+44 203 749 5797
Mitchell Chan	Oncology; Other	+1 240 477 3771
Christer Gruvris	Brilinta; Diabetes	+44 203 749 5711
Nick Stone	Respiratory; Renal	+44 203 749 5716
US toll free		+1 866 381 7277

Adrian Kemp  
Company Secretary  
AstraZeneca PLC

- 1 Details of the person discharging managerial responsibilities / person closely associated
- a) Name Pascal Soriot
- 2 Reason for the notification
- a) Position/status Chief Executive Officer
- b) Initial notification /Amendment Initial notification
- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name AstraZeneca PLC
- b) LEI PY6ZZQWO2IZFZC3IOL08
- 4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
- a) Description of the financial instrument, type of instrument Ordinary Shares of US\$0.25  
each in AstraZeneca PLC
- Identification code GB0009895292
- b) Nature of the transaction Acquisition of ordinary shares  
pursuant to a vesting under  
the AstraZeneca Deferred  
Bonus Plan, for nil  
consideration.
- c) Price(s) and volume(s) Price(s)      Volume(s)  
0              11,998
- d) Aggregated information Not applicable - single  
transaction
- Aggregated volume
- Price

Edgar Filing: ASTRAZENECA PLC - Form 6-K

e)	Date of the transaction	27 March 2018
f)	Place of the transaction	Outside a trading venue
1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Marc Dunoyer
2	Reason for the notification	
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4i	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary Shares of US\$0.25 each in AstraZeneca PLC
	Identification code	GB0009895292
b)	Nature of the transaction	Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration.
c)	Price(s) and volume(s)	Price(s)      Volume(s) 0              3,768
d)	Aggregated information	Not applicable - single transaction
	- Aggregated volume	
	- Price	
e)	Date of the transaction	27 March 2018
f)	Place of the transaction	Outside a trading venue

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 28 March 2018

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary